Lorundrostat

Highest phase reached

Phase 3

Drug type

Small molecule

Listing at source: Listed

Highest phase reached: Phase 3
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Lorundrostat
www.ebi.ac.uk

Molecular weight: 451.58
www.ebi.ac.uk

Structure (SMILES): CC(=O)N[C@H]1CC[C@H](NC(=O)CN2CCN(c3nncc(-c4ccc(C)cc4)n3)CC2)CC1
www.ebi.ac.uk

lorundrostat
Lorundrostat
lorundrostat [INN]
LORUNDROSTAT [USAN]
Lorundrostat [WHO-DD]
lorundrostat inn
lorundrostat usan
lorundrostat who dd
mls 101
mls 101 free base
MLS-101
MLS-101 FREE BASE
mls101 free base
MLS101 FREE BASE
mt 4129
mt 4129 free base
MT-4129
MT-4129 FREE BASE
mt4129 free base
MT4129 FREE BASE

CAS registry numbers

1820940-17-7

ChEMBL ID: CHEMBL5095105
www.ebi.ac.uk

InChIKey: YHGVDZULVMINCJ-MEMLXQNLSA-N
www.ebi.ac.uk

FDA ingredient codes (UNII)

KA8W5LDS6Z

First in class: No
Orphan designation: No

Pharmacology name: lorundrostat
Type: Synthetic organic
Drug name stem: -stat

Action
Inhibition
Action type
Inhibitor
Target
CYP11B1
Gene symbol
CYP11B1
Protein identifier
P15538
Median affinity
6.32
Affinity units
pKi
Action
Inhibition
Action type
Inhibitor
Target
CYP11B2
Gene symbol
CYP11B2
Protein identifier
P19099
Median affinity
8.9
Affinity units
pKi

Condition
Hypertension
Highest recorded phase
1
Condition identifier
EFO:0000537
Subject identifier
D006973
Condition
Heart Failure
Highest recorded phase
1
Condition identifier
EFO:0003144
Subject identifier
D006333
Condition
Renal Insufficiency, Chronic
Highest recorded phase
1
Condition identifier
EFO:0003884
Subject identifier
D051436

Condition identifier
EFO_0000537
Highest recorded phase
3
Condition identifier
EFO_0003144
Condition identifier
EFO_0003884
Highest recorded phase
2
Condition identifier
EFO_0004285
Highest recorded phase
2
Condition identifier
HP_0000822
Highest recorded phase
2
Condition identifier
MONDO_0005044
Highest recorded phase
3
Condition identifier
MONDO_0005252
Condition identifier
MONDO_0005300
Highest recorded phase
2
Condition identifier
MONDO_0007147
Highest recorded phase
2

Hydrogen bond acceptors: 7
Hydrogen bond donors: 2
Polar surface area: 103.35
Calculated partition coefficient (ALogP): 1.53
Prodrug: No
Chirality: Achiral
Inorganic: No
Rule-of-five violations: 0
Rotatable bonds: 6
Heavy atoms: 33
Molecular formula: C24H33N7O2
Natural product: No

Related records

Trials (5)

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

In development for (3)